Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly ...
Drugmakers are racing to develop next-generation obesity drugs that build on the success of products from Eli Lilly and Novo Nordisk. Among them, Pfizer, Roche, Boehringer Ingelheim and Amgen are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results